Drug intelligence / Profile preview

[18F]FP-GLU

Development stage
Preclinical
Lead developer
The First Affiliated Hospital of Sun Yat-sen University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[18F]FP-GLU (N-(2-[18F]fluoropropionyl)-L-glutamate) is an experimental, preclinical fluorine-18-labeled L-glutamic acid analogue developed as a positron emission tomography (PET) imaging tracer. It was originally synthesized by researchers at the PET-CT Center of the First Affiliated Hospital, Sun Yat-Sen University, to image glutamate metabolism and transport in tumors. [18F]FP-GLU is primarily transported into cells via the Na+-dependent system XAG- (including excitatory amino acid transporters EAAT1 and EAAT3) and the Na+-independent system xc- (SLC7A11). It has demonstrated high tumor-to-background contrast in preclinical models of hepatocellular carcinoma (HCC), glioma, and lung adenocarcinoma, making it a promising diagnostic tool for assessing tumor metabolic heterogeneity and response to therapies such as proton beam therapy.

Other names
18F-FP-GLU18F-FPGLU[18F]FP-GLU[18F]FPGLUN-(2-[18F]fluoropropionyl)-L-glutamateN-(2-[18F]fluoropropionyl)-L-glutamic acid
02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
central nervous system (CNS) tumorsPreclinicalActive
fibroblastic sarcomas and related tumorsPreclinicalActive
hepatocellular carcinoma (HCC)PreclinicalActive
lung adenocarcinoma (LUAD)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • The First Affiliated Hospital of Sun Yat-sen UniversityLead developer
07

Competitive landscape

Drugs on the same target
5
Drugs in the lead indication
186

Lead indication: lung adenocarcinoma (LUAD)

Most advanced in the lead indication

  1. sulfasalazineApproved
  2. atezolizumabPhase 4
  3. befotertinibPhase 4
  4. dextranPhase 4
  5. erlotinibPhase 4

Beyond the preview

Go deeper on [18F]FP-GLU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]FP-GLU.

Work on [18F]FP-GLU? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call